Internal Medicine Physician pursuing a career in academic medicine and future fellowship in hematology & oncology with a focus in malignant hematology, specific
Incredibly honored to share our hypothesis generating work demonstrating superior outcomes in female sex in patients with CD19 directed CAR T for large B cell lymphomas published @BilalAbidMD
https://t.co/bSnYWUU21V
@lymphoma#Lymsm#CARTcell#SexDisparities@lymphomahub
🚨🔥 “Female sex is associated with superior outcomes in patients treated with CAR T-cell therapy for Large B-cell Lymphoma”
N=1503, KM curves👇 [A=OS; B=PFS; C=relapse]
Congrats, @johnbehman. https://t.co/vpOrbzk7JV
#Lymsm#CARTcell#SexDisparities@lymphomahub@lymphoma
I am proud to share our work thanks to the mentorship of @nishihori presented today at #NCCN2026 "Development of an Outcome Prediction Web Application for Allogeneic Transplant in ALL." Which utilized the @CIBMTR publicly available dataset of 4,623 ALL patients @NCCN
🚨Excellent work by @BehmanJG with teasing out CAR-T outcomes based on gender. Clear signal of ⬆️ PFS in 🧘♀️vs ⛹️♂️.. Results signal CAR-T product selection based on gender and need prospective validation! @ASTCT#ASH25@CIBMTR#Lymsm#CARTCell@nmdp_org https://t.co/qk7LK1wSgV
Incredibly honored and grateful for the mentorship and support of @BilalAbidMD - Poster #1948 "Characterizing Differences in CAR-T cell Therapy Outcomes Based on Sex in Patients with Large B-cell Lymphoma" #ASH2025@ASH_hematology
Incredibly excited to have been selected to present Abstracts https://t.co/kgbNyixnas and https://t.co/bvQWeY3agF at #ASH25 in Orlando Thank you so much for the incredible support to the incredible mentorship of @BilalAbidMD and @nishihori !
Please check our recent Seminar review in @TheLancet discussing the biology of #ALL and evolution of treatment for both pediatric and adult patients
@MDAndersonNews#Leukemia
https://t.co/ZvQjUECnsF
#leusm
After a partially matched transplant, #GVHD can result. Previously, partially matched donors caused more GVHD than fully matched donors in cancer patients. A new approach, using cyclophosphamide, can prevent most GVHD. Read more: https://t.co/wPbdV37KB2
#ASH24@ASH_hematology Poster 2181 Comparative Analysis of Donor and Conditioning Intensity in the MRD and Ptcy Era in Philadelphia + Acute Lymphoblastic Leukemia (Ph+ ALL). a 12-Year Span Report of 119 Center CIBMTR Report
So excited and honored to be accepted for virtual poster “Comparative Analysis of Donor and Conditioning Intensity in the MRD and Ptcy Era in Philadelphia + Acute Lymphoblastic Leukemia (Ph+ ALL). a 12-Year Span Report of 119 Center CIBMTR Report” at #llmcongress2024
#HemOncMatch2025
@HemOncFellows@llmcongress #oncology #bloodcancer #education #myeloma #lymphoma #leukemia #AML #CLL #all
@OncLearnNetwork